Currently Available Antiepileptic Drugs

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 4-11

  Schachter, Steven C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antiepileptic drug; Epilepsy; refractory; seizure; side effects

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CIMETIDINE; CONTRACEPTIVE AGENT; DEXTROPROPOXYPHENE; DILTIAZEM; ERYTHROMYCIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUOXETINE; GABAPENTIN; ISONIAZID; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTEK; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VERAPAMIL; VILOXAZINE; ZONISAMIDE;

ABDOMINAL PAIN; ABSENCE; ACNE; AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANHIDROSIS; ANOREXIA; ANXIETY; APLASTIC ANEMIA; APPETITE; ARTICLE; ASTHENIA; ATAXIA; BEHAVIOR CHANGE; BLURRED VISION; BONE MARROW SUPPRESSION; CAPILLARY RESISTANCE; CEREBELLUM ATROPHY; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DERMATITIS; DIARRHEA; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSARTHRIA; DYSPHASIA; EPILEPSY; ERYTHEMA MULTIFORME; FACE COARSENING; FACE DISORDER; FATIGUE; FETUS DISEASE; FLAPPING TREMOR; FLUID RETENTION; FOLIC ACID DEFICIENCY; GINGIVA HYPERPLASIA; HAIR LOSS; HEPATITIS; HICCUP; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERTHERMIA; HYPONATREMIA; INSOMNIA; KIDNEY FAILURE; LENNOX GASTAUT SYNDROME; LETHARGY; LIBIDO DISORDER; LIVER FAILURE; LIVER METABOLISM; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHADENOPATHY; MEASLES LIKE RASH; MENSTRUAL IRREGULARITY; MENTAL CONCENTRATION; MUSCLE WEAKNESS; MYOCLONUS SEIZURE; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEURAL TUBE DEFECT; NEUROTOXICITY; NYSTAGMUS; OSTEOPENIA; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SEDATION; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SLURRED SPEECH; SOMNOLENCE; SPINA BIFIDA; STEVENS JOHNSON SYNDROME; STUPOR; SWEATING; TERATOGENESIS; TERATOGENICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNSTEADINESS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; EPILEPSY; HUMANS;

EID: 33846189811     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.11.005     Document Type: Article

References (78)

1. Schachter S.C. Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors. Expert Rev Neurother 6 (2006) 111-118
2. Schachter S.C. Improving quality of life beyond seizure control. Epileptic Disord 7 suppl 1 (2005) 34-38
3. Asconape J.J. Some common issues in the use of antiepileptic drugs. Semin Neurol 22 (2002) 27-39
4. Brodie M.J., Schachter S.C., and Kwan P. Epilepsy. 3rd ed. (2005), Health Press, Oxford, England
5. Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. Antiepileptic drugs. 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia
6. In: Wyllie E., Gupta A., and Lachhwani D.K. (Eds). The treatment of epilepsy (2006), Lippincott Williams & Wilkins, Philadelphia
7. Deckers C.L., Hekster Y.A., Keyser A., van Lier H.J., Meinardi H., and Renier W.O. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 42 (2001) 1387-1394
8. Genton P., Gelisse P., Thomas P., and Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?. Neurology 55 (2000) 1106-1109
9. Mockenhaupt M., Messenheimer J., Tennis P., and Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 64 (2005) 1134-1138
10. Isojarvi J.I., Huuskonen U.E., Pakarinen A.J., Vuolteenaho O., and Myllyla V.V. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia 42 (2001) 741-745
11. Yerby M.S. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 61 (2003) S23-S26
12. Kaaja E., Kaaja R., and Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 60 (2003) 575-579
13. Artama M., Auvinen A., Raudaskoski T., Isojarvi I., and Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64 (2005) 1874-1878
14. Spina E., and Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43 (2002) 37-44
15. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16 (2002) 263-272
16. Macdonald R.L., and Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia 36 suppl 2 (1995) S2-S12
17. Sato S., White B.G., Penry J.K., Dreifuss F.E., Sackellares J.C., and Kupferberg H.J. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 32 (1982) 157-163
18. Meador K.J. Cognitive outcomes and predictive factors in epilepsy. Neurology 58 (2002) S21-S26
19. Mattson R.H. Parenteral antiepileptic/anticonvulsant drugs. Neurology 46 (1996) S8-S13
20. Theodore W.H., Porter R.J., and Raubertas R.F. Seizures during barbiturate withdrawal: relation to blood level. Ann Neurol 22 (1987) 644-647
21. Holmes L.B., Wyszynski D.F., and Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 61 (2004) 673-678
22. Willmore L.J. Epilepsy emergencies: the first seizure and status epilepticus. Neurology 51 (1998) S34-S38
23. Browne T.R., Kugler A.R., and Eldon M.A. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 46 (1996) S3-S7
24. Kaneko S., Battino D., Andermann E., et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 33 (1999) 145-158
25. Birnbaum A., Hardie N.A., Leppik I.E., et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 60 (2003) 555-559
26. Baumel I.P., Gallagher B.B., and Mattson R.H. Phenylethylmalonamide (PEMA). An important metabolite of primidone. Arch Neurol 27 (1972) 34-41
27. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
28. Venkataraman V., and Wheless J.W. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 35 (1999) 147-153
29. Wheless J., and Venkataraman V. Safety of high intravenous valproate loading doses in epilepsy patients. J Epilepsy 11 (1998) 319-324
30. Morrell M.J. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 44 (2003) 11-20
31. Isojarvi J.I., Tauboll E., Tapanainen J.S., et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 42 (2001) 305-310
32. Herzog A.G., and Schachter S.C. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia 42 (2001) 311-315
33. Duncan S., Mercho S., Lopes-Cendes I., et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 42 (2001) 750-753
34. Rho J.M., Donevan S.D., and Rogawski M.A. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acid A receptors. Ann Neurol 35 (1994) 229-234
35. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut Syndrome). N Engl J Med 328 (1993) 29-33
36. Ketter T.A., Malow B.A., Flamini R., et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 23 (1996) 129-137
37. Pellock J.M., and Brodie M.J. Felbamate: 1997 update. Epilepsia 38 (1997) 1261-1264
38. Carrazana E.J., and Wheeler S.D. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 56 (2001) 1424-1425
39. Guerrini R., Dravet C., Genton P., Belmonte A., Kaminska A., and Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39 (1998) 508-512
40. Kanner A.M., and Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 55 (2000) 588-591
41. Faught E., Morris G., Jacobson M., et al., Postmarketing Antiepileptic Drug Survey (PADS) Group. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Epilepsia 40 (1999) 1135-1140
42. Guberman A.H., Besag F.M., Brodie M.J., et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 40 (1999) 985-991
43. Tran T.A., Leppik I.E., Blesi K., Sathanandan S.T., and Remmel R. Lamotrigine clearance during pregnancy. Neurology 59 (2002) 251-255
44. Marson A.G., Hutton J.L., Leach J.P., et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46 (2001) 259-270
45. Harden C. Safety profile of levetiracetam. Epilepsia 42 (2001) 36-39
46. Ragueneau-Majlessi I., Levy R.H., and Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 43 (2002) 697-702
47. Radtke R.A. Pharmacokinetics of levetiracetam. Epilepsia 42 (2001) 24-27
48. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85 (2000) 77-85
49. Shorvon S. Oxcarbazepine: a review. Seizure 9 (2000) 75-79
50. Schmidt D., and Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 1 (2000) 396-405
51. Lauria-Horner B.A., and Pohl R.B. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 12 (2003) 663-672
52. French J.A., Kugler A.R., Robbins J.L., Knapp L.E., and Garofalo E.A. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60 (2003) 1631-1637
53. Schachter S.C. A review of the antiepileptic drug tiagabine. Clin Neuropharmacol 22 (1999) 312-317
54. Kellinghaus C., Dziewas R., and Ludemann P. Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature. Seizure 11 (2002) 243-249
55. Schachter S.C. Pharmacology and clinical experience with tiagabine. Expert Opin Pharmacother 2 (2001) 179-187
56. Leppik I.E., Gram L., Deaton R., and Sommerville K.W. Safety of tiagabine: summary of 53 trials. Epilepsy Res 33 (1999) 235-246
57. Lau A.H., Gustavson L.E., Sperelakis R., et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 38 (1997) 445-451
58. Mula M., Trimble M.R., Thompson P., and Sander J.W. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60 (2003) 1104-1107
59. Lee S., Sziklas V., Andermann F., et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 44 (2003) 339-347
60. Cerminara C., Seri S., Bombardieri R., Pinci M., and Curatolo P. Hypohidrosis during topiramate treatment: a rare and reversible side effect. Pediatr Neurol 34 (2006) 392-394
61. Johannessen S.I. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia 38 suppl 1 (1997) S18-S23
62. Kyllerman M., and Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 29 (1998) 109-114
63. Kubota M., Nishi-Nagase M., Sakakihara Y., et al. Zonisamide-induced urinary lithiasis in patients with intractable epilepsy. Brain Dev 22 (2000) 230-233
64. Knudsen J.F., Thambi L.R., Kapcala L.P., and Racoosin J.A. Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol 28 (2003) 184-189
65. Shinoda M., Akita M., Hasegawa M., Hasegawa T., and Nabeshima T. The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. Biol Pharm Bull 19 (1996) 1090-1092
66. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1261-1273
67. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1252-1260
68. Hixson J.D., and French J.A. Guidelines for new antiepileptic drug evaluation. Rev Neurol Dis 1 suppl 1 (2004) S18-S26
69. Karceski S., Morrell M.J., and Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 7 suppl 1 (2005) S1-S64 ; quiz S65-S67
70. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
71. Lhatoo S.D., Wong I.C., Polizzi G., and Sander J.W. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41 (2000) 1592-1596
72. Eadie M.J. Can anticonvulsant drug therapy 'cure' epilepsy?. CNS Drugs 15 (2001) 679-690
73. Berg A.T., and Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 44 (1994) 601-608
74. Shinnar S., and Berg A.T. Does antiepileptic drug therapy prevent the development of "chronic" epilepsy?. Epilepsia 37 (1996) 701-708
75. Temkin N.R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 42 (2001) 515-524
76. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69 (2006) 273-294
77. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Exp Opin Investig Drugs 15 (2006) 637-647
78. Schmidt D., and Rogawski M.A. New strategies for the identification of drugs to prevent the development or progression of epilepsy. Epilepsy Res 50 (2002) 71-78